Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Früh

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 10, 2022
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatmentKatarzyna Furrer, Walter Weder, Eric Innocents Eboulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Management of Stage III Non-Small-Cell Lung Cancer: ASCO GuidelineMegan E Daly, Navneet Singh, Nofisat Ismaila, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung CancerMarcel P Trefny, Sacha I Rothschild, Franziska Uhlenbrock, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastasesLorenz Frehner, Sämi Schär, Stefanie Hayoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung CancerMartin Reck, Thomas Wehler, Francisco Orlandi, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 10, 2022
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatmentKatarzyna Furrer, Walter Weder, Eric Innocents Eboulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Management of Stage III Non-Small-Cell Lung Cancer: ASCO GuidelineMegan E Daly, Navneet Singh, Nofisat Ismaila, et al.
JTO Clinical and Research Reports|December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, Lisa Holer, Katrin Gysel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung CancerMarcel P Trefny, Sacha I Rothschild, Franziska Uhlenbrock, et al.
Pageof 10